Disease relevance of EPHA7

• D6S1056 microsatellite marker within EPHA7 gene is deleted in prostate cancer [1].

High impact information on EPHA7

• This population was found to harbor transcripts of the Hek8 and Hek11 members of this gene family [2].
• The developmentally regulated expression of Hek11 during fetal B lymphopoiesis suggests a role for this gene in pre/pro-B cell expansion and/or differentiation and defines a difference in progenitor B cell populations isolated from fetal versus adult human bone marrow [2].
• In contrast, the Hek11 transcript was exclusively found in fetal bone marrow pro-B cells and pre-B cells, but not in more mature fetal B-lineage cells [2].
• All adult B-lineage cells, from early pro-B cells to end-stage plasma cells, lacked Hek11 transcripts [2].
• Because five TCF/LEF-binding sites were identified within the 5'-promoter region of the EPHA7 gene, comparative genomics analyses on EPHA7 orthologs were further performed [1].

Biological context of EPHA7

• EPHA7 is a target of systems medicine, especially in the fields of regenerative medicine and oncology [1].
• Deletion and/or promoter CpG hypermethylation could explain the EPHA7 down-regulation in human tumors [1].
• Regulated expression of the Eph-related receptor tyrosine kinase Hek11 in early human B lymphopoiesis [2].

Regulatory relationships of EPHA7

• Expression analysis of these genes in prostate cancer specimens showed CA1 to be highly expressed in bone metastasis but not expressed in primary tumor and EPHA7 to be expressed in normal prostate and primary tumor but not bone metastasis [3].

References